142 related articles for article (PubMed ID: 36937484)
21. Tumor markers for diagnosis, monitoring of recurrence and prognosis in patients with upper gastrointestinal tract cancer.
Jing JX; Wang Y; Xu XQ; Sun T; Tian BG; Du LL; Zhao XW; Han CZ
Asian Pac J Cancer Prev; 2014; 15(23):10267-72. PubMed ID: 25556459
[TBL] [Abstract][Full Text] [Related]
22. CEA, CA 242, CA 19-9, CA 72-4 and hCGbeta in the diagnosis of recurrent colorectal cancer.
Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Järvinen H; Haglund C
Tumour Biol; 2004; 25(5-6):228-34. PubMed ID: 15627885
[TBL] [Abstract][Full Text] [Related]
23. The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study.
Takahashi Y; Takeuchi T; Sakamoto J; Touge T; Mai M; Ohkura H; Kodaira S; Okajima K; Nakazato H;
Gastric Cancer; 2003; 6(3):142-5. PubMed ID: 14520526
[TBL] [Abstract][Full Text] [Related]
24. Clinical utility of CA 72-4 serum marker in the staging and immediate post-surgical management of gastric cancer patients.
Spila A; Roselli M; Cosimelli M; Ferroni P; Cavaliere F; Arcuri R; Tedesco M; Carlini S; D'Alessandro R; Perri P; Casciani CU; Greiner JW; Schlom J; Guadagni F
Anticancer Res; 1996; 16(4B):2241-7. PubMed ID: 8694550
[TBL] [Abstract][Full Text] [Related]
25. Clinical assessment and prognostic evaluation of tumor markers in patients with gastric cancer.
Jiexian J; Xiaoqin X; Lili D; Baoguo T; Ting S; Xianwen Z; Cunzhi H
Int J Biol Markers; 2013 Jun; 28(2):192-200. PubMed ID: 23787496
[TBL] [Abstract][Full Text] [Related]
26. Analyzing Gastric Lavage of Gastric Cancer Patients: A Prospective Observational Study on Cytopathology and Determination of Intragastric CEA, CA 19.9, CA 72.4, and CA 50.
Virgilio E; Giarnieri E; Montagnini M; D''Urso R; Proietti A; Mesiti A; Giovagnoli MR; Mercantini P; Cavallini M; Balducci G
Acta Cytol; 2016; 60(2):161-6. PubMed ID: 27096417
[TBL] [Abstract][Full Text] [Related]
27. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.
Lai IR; Lee WJ; Huang MT; Lin HH
Hepatogastroenterology; 2002; 49(46):1157-60. PubMed ID: 12143226
[TBL] [Abstract][Full Text] [Related]
28. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
29. Preoperative serum levels of CA 72-4, CEA, CA 19-9, and alpha-fetoprotein in patients with gastric cancer.
Mattar R; Alves de Andrade CR; DiFavero GM; Gama-Rodrigues JJ; Laudanna AA
Rev Hosp Clin Fac Med Sao Paulo; 2002; 57(3):89-92. PubMed ID: 12118264
[TBL] [Abstract][Full Text] [Related]
30. Comparison of CEA and CA19-9 as a predictive factor for recurrence after curative gastrectomy in gastric cancer.
Shibata C; Nakano T; Yasumoto A; Mitamura A; Sawada K; Ogawa H; Miura T; Ise I; Takami K; Yamamoto K; Katayose Y
BMC Surg; 2022 Jun; 22(1):213. PubMed ID: 35655198
[TBL] [Abstract][Full Text] [Related]
31. Receiver operating characteristic (ROC) curve analysis of the tumor markers CEA, CA 19-9 and CA 72-4 in gastric cancer.
Fernández-Fernández L; Tejero E; Tieso A; Rabadán L; Munoz M; Santos I
Int Surg; 1996; 81(4):400-2. PubMed ID: 9127805
[TBL] [Abstract][Full Text] [Related]
32. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.
Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Haglund C
Anticancer Res; 2002; 22(4):2311-6. PubMed ID: 12174919
[TBL] [Abstract][Full Text] [Related]
33. Comparison of Serum CA72-4 and CEA Levels in Patient with Endoscopically Suspected Gastric Carcinoma.
Rehena Z; Ghosh CK; Afroz F; Alam MB; Ferdousi S; Mahmuduzzaman M; Sultana T; Ahmed AN
Mymensingh Med J; 2015 Jul; 24(3):542-9. PubMed ID: 26329953
[TBL] [Abstract][Full Text] [Related]
34. The clinical efficacy of CA 72-4 as serum marker for gastric cancer in comparison with CA19-9 and CEA.
Kodama I; Koufuji K; Kawabata S; Tetsu S; Tsuji Y; Takeda J; Kakegawa T
Int Surg; 1995; 80(1):45-8. PubMed ID: 7657491
[TBL] [Abstract][Full Text] [Related]
35. The tumor markers CEA, TPA and CA 19-9 in gastric cancer.
Putzki H; Reichert B; Jablonski M; Heymann H
Dtsch Z Verdau Stoffwechselkr; 1988; 48(3-4):145-8. PubMed ID: 3234297
[TBL] [Abstract][Full Text] [Related]
36. Combined preoperative concentrations of CEA, CA 19-9, and 72-4 for predicting outcomes in patients with gastric cancer after curative resection.
Liu X; Qiu H; Liu J; Chen S; Xu D; Li W; Zhan Y; Li Y; Chen Y; Zhou Z; Sun X
Oncotarget; 2016 Jun; 7(23):35446-53. PubMed ID: 27147574
[TBL] [Abstract][Full Text] [Related]
37. CEA and CA 19-9 are still valuable markers for the prognosis of colorectal and gastric cancer patients.
Sisik A; Kaya M; Bas G; Basak F; Alimoglu O
Asian Pac J Cancer Prev; 2013; 14(7):4289-94. PubMed ID: 23991991
[TBL] [Abstract][Full Text] [Related]
38. Gastric cancer: tumor markers as predictive factors for preoperative staging.
Cidón EU; Bustamante R
J Gastrointest Cancer; 2011 Sep; 42(3):127-30. PubMed ID: 20499209
[TBL] [Abstract][Full Text] [Related]
39. [Tumor markers in the upper intestinal tract--stomach and pancreas].
Pointner R; Conrad F; Schwab G
Wien Klin Wochenschr; 1989 Jul; 101(14):482-4. PubMed ID: 2773485
[TBL] [Abstract][Full Text] [Related]
40. Clinical evaluation of carcinoembryonic and carbohydrate antigens as cancer biomarkers to monitor palliative chemotherapy in advanced stage gastric cancer.
Abbas M; Ahmed A; Khan GJ; Baig MMFA; Naveed M; Mikrani R; Cao T; Naeem S; Shi M; Dingding C
Curr Probl Cancer; 2019 Feb; 43(1):5-17. PubMed ID: 30172422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
